Castle Biosciences, Inc. - Common stock (NQ:CSTL)

33.48 -3.17 (-8.66%)

Delayed Quote Updated: 3:20 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting

October 11, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

October 10, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences: Q2 Earnings Insights ↗

August 08, 2022

Castle Biosciences (NASDAQ:CSTL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma

September 23, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference

September 21, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day

September 20, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association

September 13, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences's Return On Capital Employed Overview ↗

September 01, 2022

According to data from Benzinga Pro, during Q2, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $34.84 million. Despite a 93.31% increase in earnings, the company posted a loss of $1.65...

Via Benzinga

Castle Biosciences to Participate in Upcoming Investor Conferences

September 01, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Host Investor Day on Sept. 20, 2022

August 24, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Reports Second Quarter 2022 Results

August 08, 2022

From Castle Biosciences, Inc.

Via Business Wire

American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus

August 04, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 03, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8

July 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma

July 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma

July 20, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Honored with a 2022 Arizona Top Workplace Award

July 18, 2022

From Castle Biosciences, Inc.

Via Business Wire

Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative

June 23, 2022

From Castle Biosciences, Inc.

Via Business Wire

Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday ↗

June 24, 2022

Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown...

Via Benzinga

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022

June 22, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Announces Support for OHSU’s War on Melanoma™

June 20, 2022

From Castle Biosciences, Inc.

Via Business Wire

Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma

June 14, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the JMP Securities Life Sciences Conference

June 08, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award

May 27, 2022

From Castle Biosciences, Inc.

Via Business Wire

Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting

May 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia

May 24, 2022

From Castle Biosciences, Inc.

Via Business Wire

Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

May 20, 2022

From Castle Biosciences

Via Business Wire

Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC

May 19, 2022

From Castle Biosciences, Inc.

Via Business Wire

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years ↗

May 11, 2022

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Via InvestorPlace

Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings

May 10, 2022

From Castle Biosciences, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.